No material news briefings were provided for AbbVie Inc. in the context window for this reporting cycle. The report is therefore grounded in regulatory filings, ownership disclosures, and macroeconomic data as detailed below.
AbbVie's trailing twelve-month revenue through 31 March 2026 stood at $62.82 billion, reflecting 12.43% year-over-year growth [SEC 10-Q - ABBV - 2026-03-31]. Gross margin was recorded at 67.37%, with an operating margin of 24.41% and a net margin of 5.79% [SEC 10-Q - ABBV - 2026-03-31]. Net income on a TTM basis was $3.64 billion, while EPS declined 45.83% year-over-year [SEC 10-Q - ABBV - 2026-03-31]. The company held $9.39 billion in cash against total debt of $64.50 billion, producing a notably leveraged balance sheet position [SEC 10-Q - ABBV - 2026-03-31]. The reported P/E ratio stood at 107.04 [SEC 10-Q - ABBV - 2026-03-31].
Insider activity over the past 30 days comprised 11 transactions with a mixed directional profile and a net value of zero, indicating no dominant buy or dispose trend among reported insiders [SEC Form 4 - ABBV - 2026-05]. On the institutional side, Bridgewater added 114% to its ABBV position and Millennium added 61%, while Citadel reduced its holding by 11% and AQR Capital reduced by 23% [SEC 13F - Bridgewater - Q1 2026] [SEC 13F - Millennium - Q1 2026] [SEC 13F - Citadel - Q1 2026] [SEC 13F - AQR Capital - Q1 2026]. These divergent moves among large institutional filers were the primary trigger for this report.
The prevailing macro backdrop shows the 10-year US Treasury yield at 4.57% and the 2-year at 4.08%, producing a normal yield curve spread of 49 basis points [FRED DGS10] [FRED DGS2]. AbbVie carries substantial long-term debt, making the interest rate environment a relevant data point for assessing its financing conditions as reported in current filings.